Journal of Dermatological Treatment最新文献

{"title":"Risk of fetal malformation, spontaneous abortion, and adverse pregnancy outcomes after gestational terbinafine exposure: a systematic review.","authors":"Philipp Foessleitner,&nbsp;Alex Farr,&nbsp;Julia Deinsberger","doi":"10.1080/09546634.2022.2110837","DOIUrl":"https://doi.org/10.1080/09546634.2022.2110837","url":null,"abstract":"<p><p>Fungal skin and nail infections are common health issues affecting an estimated 10%-20% of the world's population. The antifungal agent terbinafine shows broad-spectrum activity against a wide range of fungal species and is commonly prescribed as a first-line treatment for dermatomycoses and onychomycoses. However, owing to insufficient data regarding embryotoxicity and adverse pregnancy outcomes, treatment with terbinafine is currently not recommended in pregnancy and breastfeeding. This systematic review aimed to evaluate the effects of gestational terbinafine exposure on congenital malformations, spontaneous abortions, and adverse pregnancy outcomes. PubMed/MEDLINE, EMBASE, and clinicaltrials.org were searched to retrieve relevant reports up to March 2022. Two investigators independently screened the articles, extracted the data, and performed a quality assessment using the Newcastle-Ottawa Scale. Two cohort and two case-control studies were eligible for inclusion. Overall, the study showed the absence of an increased risk of congenital malformations, spontaneous abortion, preterm birth, small for gestational age, low birth weight, or stillbirth, following systemic or topical terbinafine exposure during pregnancy. In conclusion, the use of systemic and topical terbinafine during pregnancy can be regarded as safe for mothers and unborn children. The current recommendation concerning gestational terbinafine administration should be reconsidered.</p>","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"33 8","pages":"3073-3079"},"PeriodicalIF":2.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10414205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of tolerability and efficacy of a topical emulgel containing nanoliposomal ruxolitinib phosphate in the treatment of mild atopic dermatitis: a before-after single group pilot study.","authors":"Atefeh Naeimifar,&nbsp;Saman Ahmad Nasrollahi,&nbsp;Aniseh Samadi,&nbsp;Zeinab Aryanian,&nbsp;Hamid Akbari Javar,&nbsp;Mohammadreza Rouini,&nbsp;Mansour Nassiri Kashani,&nbsp;Alireza Firooz","doi":"10.1080/09546634.2022.2112138","DOIUrl":"https://doi.org/10.1080/09546634.2022.2112138","url":null,"abstract":"<p><strong>Background: </strong>Ruxolitinib is a JAK1/2 inhibitor, which inhibits the signal transduction of interferon-gamma, a cytokine implicated in the pathogenesis of atopic dermatitis (AD). In this before-after single group phase IIA pilot study, we investigated the efficacy of topical nanoliposomal ruxolitinib phosphate (RuxoLip) emulgel in mild AD.</p><p><strong>Methods: </strong>Clinical evaluation was conducted on 10 patients with mild AD. The efficacy of the product as well as patient satisfaction was evaluated by local scoring atopic dermatitis (SCORAD) of AD. In addition, trans-epidermal water loss (TEWL), stratum corneum (SC) hydration, sebum, erythema, melanin content, and ultrasonographic parameters were measured before, and two and four weeks after treatment.</p><p><strong>Results: </strong>Four weeks of treatment reduced SCORAD, itching, and burning (<i>p</i> = .001, .001, and .001, respectively) and increased hydration, sebum, and epidermal density (<i>p</i> = .001, .018, and .037, respectively). SCORAD and other skin biophysical parameters improved within two weeks of treatment and then were in plateau for up to four weeks.</p><p><strong>Conclusions: </strong>The topical ruxolitinib emulgel has good short-term efficacy and tolerability.</p>","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"33 8","pages":"3160-3164"},"PeriodicalIF":2.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10414212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of topical imiquimod induced fatigue.","authors":"Justin Raman,&nbsp;Elizabeth Bisbee,&nbsp;Tricia A Missall,&nbsp;Sami K Saikaly","doi":"10.1080/09546634.2022.2125266","DOIUrl":"https://doi.org/10.1080/09546634.2022.2125266","url":null,"abstract":"<p><p>Topical imiquimod is used for a variety of common dermatologic lesions, including melanoma <i>in-situ</i>. As an immunomodulator, it is relatively well tolerated with minimal side effects, including scaling, erythema, and edema. Here we present a rare systemic adverse effect, where our patient experienced debilitating severe fatigue when applying imiquimod to a single lesion. Clinicians should be mindful of this side effect and counsel patients appropriately.</p>","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"33 8","pages":"3202-3204"},"PeriodicalIF":2.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10759592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world clinical outcomes of treatment with brodalumab in patients with moderate-to-severe psoriasis: a retrospective, 24-month experience from four academic dermatology centers in Greece.","authors":"Evangelia Papadavid,&nbsp;Efterpi Zafeiriou,&nbsp;Sophia Georgiou,&nbsp;Angeliki-Viktoria Roussaki-Schulze,&nbsp;Theofanis Spiliopoulos,&nbsp;Eleftheria Vryzaki,&nbsp;Chrysa Oikonomou,&nbsp;Ourania Drongoula,&nbsp;Maria Boziou,&nbsp;Georgios Goudouras,&nbsp;Konstantinos Sfaelos,&nbsp;Zoi Apalla,&nbsp;Elisavet Lazaridou","doi":"10.1080/09546634.2022.2110836","DOIUrl":"https://doi.org/10.1080/09546634.2022.2110836","url":null,"abstract":"<p><strong>Objective: </strong>To assess the real-world clinical treatment outcomes with brodalumab in patients with moderate-to-severe plaque psoriasis in Greece.</p><p><strong>Materials and methods: </strong>This was a longitudinal, retrospective, real-world analysis of data from medical records of 106 patients with moderate-to-severe plaque psoriasis, treated with brodalumab for up to 24 months at four University Dermatology Centers in Greece. Efficacy assessments of psoriasis severity [Psoriasis Area and Severity Index (PASI) and Body Surface Area affected (BSA) scores] and its impact on patients' quality of life (QoL) [Dermatology Life Quality Index (DLQI) score] were evaluated at different timepoints up to 24 months.</p><p><strong>Results: </strong>Treatment with brodalumab reduced both mean PASI (14.0-1.5, <i>p</i> < .001) and BSA scores (21.6-2.5, <i>p</i> < .001) across all visits. This effect was accompanied by reduction in mean DLQI score (12.8-2.1, <i>p</i> < .001) across all visits compared with baseline. Moreover, therapeutic efficacy was affected by prior biologic treatment exposure, as biologic naïve patients had greater reductions in all scores from baseline following treatment with brodalumab (numerical for mean PASI, significant for mean BSA and DLQI scores).</p><p><strong>Conclusion: </strong>Brodalumab is effective long term, improving disease severity and health-related QoL in patients with moderate-to-severe plaque psoriasis in a real-world setting.</p>","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":" ","pages":"3053-3059"},"PeriodicalIF":2.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40414551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasis.","authors":"Kim A Papp,&nbsp;Henrik Thoning,&nbsp;Sascha Gerdes,&nbsp;Matteo Megna,&nbsp;Henrik Brandi,&nbsp;Marie Y Jablonski Bernasconi,&nbsp;Oriol Yélamos","doi":"10.1080/09546634.2022.2095330","DOIUrl":"https://doi.org/10.1080/09546634.2022.2095330","url":null,"abstract":"<p><strong>Background and objectives: </strong>Once-daily, fixed-combination calcipotriol 50 μg/g (Cal) plus betamethasone dipropionate 0.5 mg/g (BD) is available in aerosol foam and cream formulations. As no head-to-head data are available, we use a matching-adjusted indirect comparison (MAIC) approach to compare Cal/BD foam and cream.</p><p><strong>Methods: </strong>Anchored and unanchored MAIC analyses were conducted using individual patient data (IPD) from five Cal/BD foam trials and two trials of Cal/BD cream. Outcomes of interest were the proportion of patients with Physician's Global Assessment (PGA) success and the mean reduction in modified Psoriasis Area and Severity Index (mPASI).</p><p><strong>Results: </strong>In the anchored MAIC, patients were more likely to achieve PGA success after 4 weeks of Cal/BD foam than after 8 weeks of Cal/BD cream and had larger mean improvements in mPASI (<i>p</i> < .01 in EU mPASI analysis). In unanchored analyses, 4 weeks of Cal/BD foam treatment was statistically significantly more efficacious in inducing PGA success than 8 weeks of Cal/BD cream (<i>p</i> < .01 in five of six comparisons). Mean reductions in mPASI were consistently statistically significantly greater with Cal/BD foam than with Cal/BD cream.</p><p><strong>Conclusions: </strong>Use of Cal/BD foam consistently shows significantly greater improvements in PGA and mPASI outcomes, compared with Cal/BD cream.</p>","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"33 7","pages":"3005-3013"},"PeriodicalIF":2.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10508199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiarm study comparing patient-reported and clinical outcome measures in patients undergoing antipsoriatic therapy with non-biological systemic agents in a real-world setting.","authors":"Christine Fink,&nbsp;Christina Alt,&nbsp;Timo E Schank,&nbsp;Katharina Sies,&nbsp;Samuel Kilian,&nbsp;Knut Schäkel","doi":"10.1080/09546634.2022.2095329","DOIUrl":"https://doi.org/10.1080/09546634.2022.2095329","url":null,"abstract":"<p><strong>Background: </strong>Although the inclusion of patients' preferences and needs is essential for therapy adherence, the assessment of patient-reported outcome measures in clinical trials is often neglected. Therefore, the aim of this study was to quantify several patient-reported outcome measures in psoriasis patients undergoing systemic therapy in a real-life clinical setting.</p><p><strong>Methods: </strong>This clinical trial has been designed as a prospective, multiarm study to investigate the treatment satisfaction, adherence to therapy, quality of life (QoL), and clinical response in a real-life clinical setting during the initial 6 months of treatment with apremilast, methotrexate, and fumaric acids in 80 patients suffering from plaque psoriasis.</p><p><strong>Results: </strong>The treatment satisfaction for the three systemic therapies was rated 'sufficient' with a mean (±SD) Treatment Satisfaction Questionnaire for Medication (TSQM) score of 275.0 (±62.7). Most potential for improvement was seen in the 'effectiveness' domain (54.3 ± 21.5). The highest treatment satisfaction level in all four domains (convenience, effectiveness, global satisfaction, and side-effects) was seen in the methotrexate group with a mean TSQM score of 306.3 ± 50.9, followed by apremilast (267.1 ± 61.6) and fumaric acids (254.9 ± 65.0; <i>p</i> = 0.005). Analysis of the TSQM revealed a considerable discrepancy between patient-reported clinical response and the actual Psoriasis Area and Severity Index (PASI) reduction. This applies equally to the patient- <i>vs.</i> physician-reported side-effects.</p><p><strong>Conclusions: </strong>This real-life study demonstrates that an adequate assessment of antipsoriatic drugs by PASI-reduction alone is not sufficient and underlines the importance of patient-reported outcome measures not only in clinical trials, but also for improved patient care.</p>","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":" ","pages":"2997-3004"},"PeriodicalIF":2.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40405945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative anticoagulation recommendations for cutaneous oncologic surgery: a review of the literature.","authors":"Hemali Shah,&nbsp;Fabio Stefano Frech,&nbsp;Isabella Dreyfuss,&nbsp;Loren Hernandez,&nbsp;Keyvan Nouri","doi":"10.1080/09546634.2022.2097161","DOIUrl":"https://doi.org/10.1080/09546634.2022.2097161","url":null,"abstract":"<p><p>Consistent perioperative management is important to the practice of dermatologic surgery. With the widespread use of anticoagulant medications, such as aspirin, warfarin, clopidogrel, factor Xa inhibitors, and thrombin inhibitors for a number of cardiovascular indications, it is important to standardize the use of these drugs in the setting of skin cancer surgery. Limited literature is available, however, regarding recommendations for dermatological perioperative anticoagulation management. Most published manuscripts involving anticoagulation and skin cancer surgery focus on complications and outcomes rather than providing guidelines for decision-making. In addition, survey studies have largely shown that even with existing recommendations in the literature, many dermatologists continue to have varying management of these medications. Overall, this review finds compelling evidence to support the safety of continuing anticoagulation therapy, such as warfarin, aspirin, and clopidogrel throughout treatment for cutaneous malignancies. It is important that dermatologists, while having primary care and cardiology available for consultation, are aware of the safety data and feel comfortable managing their patients perioperatively.</p>","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":" ","pages":"2940-2945"},"PeriodicalIF":2.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40463097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical efficacy analysis of 110 cases of childhood vitiligo with non-surgical combined therapy.","authors":"Yuan-Yuan Liu,&nbsp;Jun-Feng Zhou,&nbsp;Yu Zhen,&nbsp;Yan Cui,&nbsp;Yang Song,&nbsp;Lei Yao,&nbsp;Shan-Shan Li","doi":"10.1080/09546634.2022.2104443","DOIUrl":"https://doi.org/10.1080/09546634.2022.2104443","url":null,"abstract":"<p><strong>Background: </strong>Vitiligo has a negative effect on children's physical and psychological health. Few studies have examined long-term treatment efficacy for childhood vitiligo. Therefore, we evaluated the long-term effectiveness of non-surgical combination therapy in pediatric patients with vitiligo and analyzed factors that affect its efficacy.</p><p><strong>Methods: </strong>Pediatric patients (⩽12 years) with vitiligo who were treated with topical corticosteroids/topical calcineurin inhibitors and phototherapy for 12 months were retrospectively studied. Short-term systemic corticosteroids were administered according to individual clinical conditions. All lesions were photographed to assess repigmentation at 3-month intervals. Clinical data, the treatment effectiveness, and factors affecting the therapeutic effect were analyzed.</p><p><strong>Results: </strong>Overall, 110 children (51 [53.6%] girls; mean [SD] age, 7.1 ± 3.0 years; 104 [94.5%] with activity status) were treated for a mean period of 23.13 ± 14.03 months (range, 5-86 months). The overall >50% repigmentation rate was 64.5%. A longer duration of treatment was associated with a higher repigmentation rate (<i>X</i><i>²</i> <i>_trend</i> = 36.229, <i>P</i> < .001). The vitiligo disease activity score at the first visit was positively correlated with the overall repigmentation rate (<i>r_s</i> = 0.301, <i>P</i> = .001).</p><p><strong>Conclusions: </strong>Treatment lasting longer than 1 year is recommended in children with vitiligo. The best repigmentation effect can be achieved by combination therapy in the rapid progression stage.</p>","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":" ","pages":"3034-3038"},"PeriodicalIF":2.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40633441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor submitted in response to 'Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study'.","authors":"Maddalena Napolitano,&nbsp;Luca Potestio,&nbsp;Francesca Di Vico,&nbsp;Gabriella Fabbrocini,&nbsp;Cataldo Patruno","doi":"10.1080/09546634.2022.2089615","DOIUrl":"https://doi.org/10.1080/09546634.2022.2089615","url":null,"abstract":"’ s ‘ Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study ’ , investigating the incidence and prognostic outcomes of SARS-CoV-2 infection in patients suffering from atopic diseases including atopic dermatitis (AD) and under treatment with dupilumab (1). Herein, we report the results of a retrospective ana-lysis enrolling 532 patients treated with dupilumab for moderate-to-severe AD attending the Dermatology Unit of the University of Naples Federico II from March 10 2020 to May 8 2022. Inclusion criteria were: age (cid:1) 18 years; dupilumab treatment at labeled dosage (600 mg loading dose at baseline, fol-lowed by 300 mg every 2 weeks) for at least 3 months before the viral infection; diagnosis of SARS-CoV-2 infection by molecu-lar or antigenic swab. A total of 109 (20.49%) subjects were included. Eighty-seven (79.82%) patients had received at least one dose of COVID-19 vaccines (mRNA or viral vector-based) available in Italy before contracting SARS-CoV-2 infection. Demographic and clinical data of patients who contracted the infection are reported in Table 1. Globally, no cases of severe infection and no hospitalizations were collected in our cohort. Thirteen (11.93%) patients reported AD worsening following SARS-CoV-2 infection. No significant statistical differences between vaccinated and nonvaccinated patients were found regarding all the variables studied. Patients with fever and/or respiratory symptoms temporarily suspended dupilumab admin-istration until the recovery from COVID-19; no treatment suspen-sion was reported in asymptomatic patients.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":" ","pages":"3066-3067"},"PeriodicalIF":2.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40071479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the onset, depth, and duration of cutaneous anesthesia between topical 10% lidocaine and EMLA creams: a randomized, intraindividual, comparative trial.","authors":"Nichchanun Junputipong,&nbsp;Salinee Rojhirunsakool,&nbsp;Poonnapa Deewongkij,&nbsp;Nanticha Kamanamool,&nbsp;Montree Udompataikul","doi":"10.1080/09546634.2022.2109566","DOIUrl":"https://doi.org/10.1080/09546634.2022.2109566","url":null,"abstract":"<p><strong>Background: </strong>The eutectic mixture of local anesthetics (EMLA) is an effective cutaneous anesthetic, although its application is time consuming and poses a risk of methemoglobinemia. Currently, the efficacy of topical 10% lidocaine cream is unclear.</p><p><strong>Objective: </strong>To compare the onset, anesthesia depth, and duration of topical 10% lidocaine and EMLA cream.</p><p><strong>Methods: </strong>The randomized, split-body, comparative trial performed on 40 participants who received a topical 10% lidocaine cream or EMLA on forearms for 15-150 min. Pain was stimulated using a 21-gauge needle insertion and evaluated with the Verbal Pain Score. Adverse effects were recorded.</p><p><strong>Results: </strong>EMLA conferred significantly better efficacy than 10% lidocaine (<i>p</i> < .001). For acceptable pain at 4-mm depth, the minimal application times were 40.88 and 45.38 min of EMLA and 10% lidocaine creams, respectively. With 60/120-min application, the maximal needle-insertion depths with acceptable pain were 6.61/9.47 mm (EMLA) and 6.01/8.94 mm (10% lidocaine). EMLA's anesthetic effect showed an early increase after removal which was sustained for 60-90 min. Both creams caused adverse effects, with EMLA showing higher proportions, although the differences were statistically insignificant.</p><p><strong>Conclusion: </strong>The efficacy of EMLA was superior to 10% lidocaine cream, especially regarding anesthesia onset and duration.</p>","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":" ","pages":"3047-3052"},"PeriodicalIF":2.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40665733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}